249 related articles for article (PubMed ID: 35315162)
1. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.
Savinkina A; Madushani RWMA; Eftekhari Yazdi G; Wang J; Barocas JA; Morgan JR; Assoumou SA; Walley AY; Linas BP; Murphy SM
Addiction; 2022 Sep; 117(9):2450-2461. PubMed ID: 35315162
[TBL] [Abstract][Full Text] [Related]
2. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
[TBL] [Abstract][Full Text] [Related]
3. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.
Walley AY; Lodi S; Li Y; Bernson D; Babakhanlou-Chase H; Land T; Larochelle MR
Addiction; 2020 Aug; 115(8):1496-1508. PubMed ID: 32096908
[TBL] [Abstract][Full Text] [Related]
4. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
[TBL] [Abstract][Full Text] [Related]
5. "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.
Dickson-Gomez J; Krechel S; Ohlrich J; Montaque HDG; Weeks M; Li J; Havens J; Spector A
Harm Reduct J; 2024 Feb; 21(1):52. PubMed ID: 38413972
[TBL] [Abstract][Full Text] [Related]
6. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
7. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use.
Noam KR; Schmutte TJ; Pirard S; Bourdon C; Langless D; Plant R
J Addict Med; 2023 May-Jun 01; 17(3):e199-e201. PubMed ID: 37267183
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.
Choi SA; Yan CH; Gastala NM; Touchette DR; Stranges PM
J Subst Use Addict Treat; 2024 May; 160():209237. PubMed ID: 38061629
[TBL] [Abstract][Full Text] [Related]
9. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting.
Morgan JR; Barocas JA; Murphy SM; Epstein RL; Stein MD; Schackman BR; Walley AY; Linas BP
JAMA Netw Open; 2020 Dec; 3(12):e2029676. PubMed ID: 33320266
[TBL] [Abstract][Full Text] [Related]
11. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
[TBL] [Abstract][Full Text] [Related]
12. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
[TBL] [Abstract][Full Text] [Related]
13. Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study.
David AR; Sian CR; Gebel CM; Linas BP; Samet JH; Sprague Martinez LS; Muroff J; Bernstein JA; Assoumou SA
J Subst Abuse Treat; 2022 Nov; 142():108870. PubMed ID: 36084559
[TBL] [Abstract][Full Text] [Related]
14. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
[TBL] [Abstract][Full Text] [Related]
15. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
Johnson K; Hills H; Ma J; Brown CH; McGovern M
Am J Drug Alcohol Abuse; 2021 Mar; 47(2):220-228. PubMed ID: 33054435
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
[No Abstract] [Full Text] [Related]
17. Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder.
Nataraj N; Rikard SM; Zhang K; Jiang X; Guy GP; Rice K; Mattson CL; Gladden RM; Mustaquim DM; Illg ZN; Seth P; Noonan RK; Losby JL
JAMA Netw Open; 2024 Apr; 7(4):e244617. PubMed ID: 38568691
[TBL] [Abstract][Full Text] [Related]
18. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
Treitler PC; Enich M; Reeves D; Crystal S
Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
[No Abstract] [Full Text] [Related]
19. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
[TBL] [Abstract][Full Text] [Related]
20. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]